Over the past two and a half decades, Epogen has generated $40 billion in sales for Amgen ( NAS: AMGN ), with Johnson & Johnson ( NYS: JNJ ) selling it under the name Procrit for treating anemia resulting from chronic kidney failure, chemotherapy, zidovudine treatment for HIV, or surgery. But after safety concerns suddenly arose, sales of Epogen fell 20% in 2011 to $2 billion. Omontys introduces a once-monthly treatment regimen, which compares favorably to Epogen's twice weekly schedule.